Neuroprotective effects of oral administration of triacetyluridine against MPTP neurotoxicity

Peter Klivenyi, Gabrielle Gardian, Noel Y. Calingasan, Lichuan Yang, Reid Von Borstel, Joel Saydoff, Susan E. Browne, M. Flint Beal

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Administration of triacetyluridine (TAU) is a means of delivering exogenous pyrimidines to the brain, which may help to compensate for bioenergetic defects. TAU has previously been shown to be neuroprotective in animal models of Huntington's and Alzheimer's diseases. We examined whether oral administration of TAU in the diet could exert significant neuroprotective effects against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity model of Parkinson's disease. Administration of TAU significantly attenuated MPTP-induced depletion of striatal dopamine and loss of tyrosine-hydroxylase-positive neurons in the substantia nigra. These findings suggest that administration of TAU may be a novel approach for treating neurodegenerative diseases associated with impaired mitochondrial function.

Original languageEnglish
Pages (from-to)87-92
Number of pages6
JournalNeuroMolecular Medicine
Volume6
Issue number2-3
Publication statusPublished - Oct 1 2004

Keywords

  • Dopamine
  • MPTP
  • Mitochondria
  • Parkinson's disease
  • Triacetyluridine

ASJC Scopus subject areas

  • Molecular Medicine
  • Neurology
  • Cellular and Molecular Neuroscience

Fingerprint Dive into the research topics of 'Neuroprotective effects of oral administration of triacetyluridine against MPTP neurotoxicity'. Together they form a unique fingerprint.

  • Cite this

    Klivenyi, P., Gardian, G., Calingasan, N. Y., Yang, L., Von Borstel, R., Saydoff, J., Browne, S. E., & Beal, M. F. (2004). Neuroprotective effects of oral administration of triacetyluridine against MPTP neurotoxicity. NeuroMolecular Medicine, 6(2-3), 87-92.